吲哚美辛联合泼尼松治疗葡萄膜炎患者的临床研究

目的观察吲哚美辛滴眼液联合泼尼松滴眼液治疗葡萄膜炎患者的临床疗效及安全性。方法将急性葡萄膜炎患者随机分为对照组和试验组。对照组给予醋酸泼尼松龙滴眼液治疗,每次2滴,tid;试验组在对照组治疗的基础上,联合吲哚美辛滴眼液治疗,每次1滴,tid。2组患者均治疗1个月。比较2组患者的临床疗效、视力、眼内压、白细胞计数(WBC)、中性粒细胞计数(NEU)、血清中肿瘤坏死因子-α(TNF-α)、白细胞介素-16(IL-16)和IL-32的表达水平,以及不良事件的发生情况。结果试验组入组47例,脱落3例,最终44例纳入分析;对照组入组47例,脱落4例,最终43例纳入分析。治疗后,试验组和对照组的总有效率分别为97.73%(43例/44例)和86.05%(37例/43例),差异无统计学意义(P>0.05)。治疗后,试验组和对照组的裸眼视力分别为0.87±0.14和0.76±0.15,眼内压分别为(15.11±1.50)和(15.87±1.77)mmHg,WBC分别为(6.95±0.84)×10^(9)和(7.45±1.14)×10^(9)·L^(-1),NEU分别为(2.21±0.63)×10^(9)和(2.51±0.66)×10^(9)·L^(-1),TNF-α分别为(17.23±2.76)和(19.17±2.95)pg·mL^(-1),IL-16分别为(68.23±9.31)和(74.41±10.01)pg·mL^(-1),IL-32分别为(78.32±9.35)和(83.15±10.53)pg·mL^(-1),差异均有统计学意义(均P<0.05)。2组患者的不良事件均以头痛、肝功能损害、白细胞减少、皮疹及睡眠障碍为主。试验组和对照组的总不良事件发生率分别为13.64%和18.60%,差异无统计学意义(P>0.05)。结论吲哚美辛滴眼液联合泼尼松滴眼液可显著改善葡萄膜炎患者的眼部症状及视力受损情况,降低患者体内的炎症水平,且不增加不良事件的发生率。

Immunization effect of purified bivalent vaccine to haemorrhagic fever with renal syndrome manufactured from primary cultured hamster kidney cells

Haemorrhagic fever with renal syndrome (HFRS) is a worldwide epidemic plaguing over thirty nations. This disease has spread across 26 provinces, cities and autonomous regions of China with an annual onsets number of more than a hundred thousand and a mortality rate of 5% to 15%, accounting for over 80% of cases in the world, and threatening the safety and health of Chinese people. 1 Analysis of serum samples over recent years indicates that the plagued areas are expanding. Instead of a single type Ⅰ or Ⅱ strain, each area now has a combination with one type predominant. 2 These demographic changes revealed a shortcoming of the monovalent vaccine in use, urging China to develop a purified bivalent vaccine based on monovalent one. This research on clinical observation and immunization effects led to a purified bivalent vaccine manufactured by Changchun Institute of Biological Products, China from primary cultured hamster kidney cells.